Flagship VentureLabs IV LLC 13D and 13G filings for Seres Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2022-07-07 5:00 pm Purchase |
2022-07-05 | 13D | Seres Therapeutics, Inc. MCRB |
Flagship VentureLabs IV LLC | 23,493,063 18.900% |
8,443,072![]() (+56.10%) |
Filing |
2020-11-25 4:30 pm Sale |
2020-11-23 | 13D | Seres Therapeutics, Inc. MCRB |
Flagship VentureLabs IV LLC | 15,049,991 16.500% |
-6,596,914![]() (-30.48%) |
Filing |